Pragmatic Trial of Messaging to Providers About Treatment of Chronic Kidney Disease
ConditionChronic Kidney Diseases
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorYale University
About this trial
This study is a cluster-randomized clinical trial to evaluate whether a tailored, user-centered, clinical decision support (CDS) tool can positively influence prescriber behavior and increase prescription of guideline-directed medical therapy (GDMT) among patients with Chronic Kidney Disease (CKD) across a single healthcare center.
Eligibility criteria
Qualifiers
Male or female, aged ≥18 years
Diagnosed with CKD defined by an eGFR ≤60 mL/min/1.732 on two occasions at least ≥3 months apart with most recent being ≤60 or eGFR 60-90 mL/min/1.73m2 with an uACR ≥30 mg/g or eGFR >90 mL/min/1.73m2 with an uACR ≥30 mg/g.
Eligible to receive at least 1 of the following CKD GDMT: ACEi/ARB, SGLT2i, MRA or GLP-1 RA based on the following criteria.
To receive an ACEi/ARB: eGFR ≥15 ml/min/1.732 and have diagnosis of hypertension based on ICD10 code or proteinuria (uACR ≥30 mg/g).
Disqualifiers
Allergy to the GDMT for which the patient is eligible
End-stage kidney disease
CKD stage 5 (eGFR <15 ml/min/1.73m2)
Glomerulonephritis (by ICD-10 code)
Trial design
Treatments tested in this trial
- Best practice alert and order set for CKD
Treatment groups
1,000 Participants
are divided into 2 treatment groupsLocations
1Yale New Haven Health06520, New HavenConnecticut, United States
Sponsors and collaborators
Yale University
Lead sponsor
Source ClinicalTrials.gov